Exousia Bio Reports No Revenue and $50,897 Net Loss for Nine Months Ending February 28, 2026

Exousia Bio, Inc., formerly known as L A M Y, reported its financial results for the nine months ending February 28, 2026, revealing a significant shift in its business focus following the acquisition of Exousia AI, Inc. The company generated no revenue during this period, a decline from $3,750 reported in the same period last year. The absence of revenue reflects the transition from its previous operations in financial education to a new strategy centered on biotechnology, specifically the development of therapeutic applications for exosomes in oncology.

The company's financial performance showed a net loss of $50,897 for the nine months ended February 28, 2026, compared to a net income of $80,659 for the same period in 2025. This change is attributed to increased operating expenses, which totaled $206,711, up from $10,632 in the prior year. The rise in expenses is primarily due to research and development costs of $161,426 and professional fees associated with the acquisition and the new business plan. The cost of goods sold was recorded at $62,108, resulting in a gross loss for the period.

In terms of operational developments, Exousia Bio underwent a significant change in management and corporate structure following the acquisition of Exousia AI on November 17, 2025. The company issued 62,223,000 shares of common stock to the shareholders of Exousia AI, which has now become its wholly-owned subsidiary. The company also changed its name to Exousia Bio, Inc. and increased its authorized common stock to 100 million shares. As of February 28, 2026, the company reported total assets of $22,050,670, primarily consisting of $22,050,000 in intangible assets related to the acquisition.

Despite these developments, Exousia Bio faces challenges regarding its liquidity and ability to continue as a going concern. As of the reporting date, the company had no cash and a working capital deficit of $261,023. The management has indicated that it will need to secure additional capital to meet its operational needs and fulfill obligations, including a $250,000 convertible promissory note that matured on March 26, 2026. The company plans to pursue funding through equity or convertible debt financing, but there are no assurances that such financing will be available on favorable terms.

Looking ahead, Exousia Bio's management is focused on advancing its biotechnology initiatives while navigating the financial challenges posed by its transition. The company has not yet established a revenue-generating operation under its new business model, and its future performance will depend on the successful development and commercialization of its product candidates. The management's ability to secure necessary funding will be critical to the company's sustainability and growth in the coming months.